BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31355251)

  • 1. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial Cancer.
    Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B
    Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of alternative splicing events in endometrial cancer prognosis.
    Liu J; Mi C; Long W; Sun T
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
    Yang L; He Y; Zhang Z; Wang W
    PeerJ; 2019; 7():e8245. PubMed ID: 31844595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.
    Gao L; Xie ZC; Pang JS; Li TT; Chen G
    Aging (Albany NY); 2019 Jan; 11(1):263-283. PubMed ID: 30640723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
    Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
    BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
    Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
    Ye P; Yang Y; Zhang L; Zheng G
    Front Oncol; 2021; 11():658262. PubMed ID: 34676158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
    Zhang D; Zou D; Deng Y; Yang L
    J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
    Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
    J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
    Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
    PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
    Li Y; Guo D
    BMC Cancer; 2021 Aug; 21(1):958. PubMed ID: 34445990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma.
    Ying J; Wang Q; Xu T; Lyu J
    Cancer Med; 2018 Jun; 7(6):2601-2611. PubMed ID: 29665298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
    Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
    Front Oncol; 2021; 11():705929. PubMed ID: 34722250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.